Biodesix, Inc.

Equities

BDSX

US09075X1081

Healthcare Facilities & Services

Delayed Nasdaq 01:45:24 2024-04-16 pm EDT 5-day change 1st Jan Change
1.225 USD -2.00% Intraday chart for Biodesix, Inc. -3.54% -33.42%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Biodesix, Inc. announced that it has received $34.999422 million in funding CI
Top Midday Decliners MT
Biodesix, Inc. announced that it expects to receive $34.999422 million in funding CI
Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center MT
Biodesix Announces New Master Collaborative Research Agreement with Memorial Sloan Kettering Cancer Center CI
Transcript : Biodesix, Inc., Q4 2023 Earnings Call, Mar 01, 2024
Biodesix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Biodesix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Biodesix, Inc. Provides Revenue Guidance for the Year 2024 CI
Earnings Flash (BDSX) BIODESIX Posts Q4 Revenue $14.7M MT
Biodesix, Inc. Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method CI
Transcript : Biodesix, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (BDSX) BIODESIX Reports Q3 Revenue $13.5M, vs. Street Est of $14.4M MT
Biodesix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Biodesix, Inc. Provides Revenue Guidance for the Year 2023 CI
Transcript : Biodesix, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 12:15 PM
Biodesix, Inc. Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer CI
Biodesix, Inc. Announces Presentation of New Nodify XL2(R) Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer CI
Transcript : Biodesix, Inc., Q2 2023 Earnings Call, Aug 07, 2023
Biodesix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (BDSX) BIODESIX Reports Q2 Revenue $11.9M, vs. Street Est of $11.7M MT
Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2023 CI
Biodesix Says Study Evaluating Nodify XL2 Test for Benign Lung Nodules Achieves Primary Endpoint; Shares Rise Pre-Bell MT
Biodesix, Inc. Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating That the Nodify XL2 Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules CI
Biodesix, Inc. Receives Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services CI
Chart Biodesix, Inc.
More charts
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.25 USD
Average target price
3.5 USD
Spread / Average Target
+180.00%
Consensus
  1. Stock Market
  2. Equities
  3. BDSX Stock
  4. News Biodesix, Inc.
  5. Morgan Stanley Lowers Biodesix's Price Target to $5 From $7, Maintains Equalweight Rating